Miura H, et al. - In order to investigate whether sodium-glucose cotransporter–2 (SGLT-2) inhibitors could increase appetite by affecting related hormones, researchers studied the effects of the SGLT-2 inhibitor ipragliflozin in individuals with suboptimally controlled type 2 diabetes, including those on appetite-regulating hormones. Study participants included 96 patients with a BMI of ≥ 22 kg/m² who were treated with ipragliflozin (50 mg/day) for 16 weeks. According to findings, ipragliflozin improved glycemic control and reduced body weight but also lowered serum leptin levels, which might increase appetite. At 2 and 8 weeks, the visual analog scale score for hunger was significantly increased.